PRIOR AUTHORIZATION CRITERIA

DRUG CLASS INSOMNIA AGENTS

BRAND NAME (generic)

BELSOMRA (suvorexant)

DAYVIGO (lemborexant)

Status: CVS Caremark Criteria Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Belsomra

Belsomra (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Dayvigo

Dayvigo (lemborexant) is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

 The requested drug is being prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance

AND

- Potential factors contributing to sleep disturbances have been addressed (e.g., inappropriate sleep hygiene and sleep environment issues) as well as treatable medical/psychiatric disorders that are co-morbid with insomnia AND
- If the patient is less than 65 years of age, the patient experienced an inadequate treatment response, intolerance or contraindication to a generic non-benzodiazepine sedative-hypnotic (e.g., eszopiclone, zaleplon, zolpidem) OR a short/intermediate-acting benzodiazepine (e.g., temazepam, triazolam)

Quantity Limits apply. 30 tablets/month

REFERENCES

- Belsomra [package insert]. Whitehouse Station, NY: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; July 2018.
- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. http://online.lexi.com/. Accessed March 2019.
- 3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. http://www.micromedexsolutions.com/. Accessed March 2019.

Insomnia Agents (Belsomra, Dayvigo) Policy 1177-C 03-2019(2).docx

©2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

- 4. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med.* 2017;13(2):307-349.
- 5. Sateia MJ. International Classification of Sleep Disorders: highlights and modifications. *CHEST*. 2014; 146 (5): 1387-1394. doi: 10.1378/chest.14-0970
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med.* Epub, 2016. 165(2):125-33. doi: 10.7326/M15-2175. Epub 2016 May 3.
- 7. Morgenthaler T; Kramer M; Alessi C et al. Practice parameters for the psychological and behavioral treatment of insomnia: An update. An American Academy of Sleep Medicine report. *SLEEP* 2006; 29(11):1415-1419.
- 8. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med 2008*; 4(5):487-504.
- 9. NCQA. 2018. (on line) www.ncga.org. Accessed March 2019.
- 10. Albert, S, Colombi, A, et al. Potentially Inappropriate Medications and Risk of Hospitalization in Retirees. *Drugs Aging* 2010 May; 27(5):407-415.
- 11. The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. American Geriatrics Society. 2015.
- 12. Hanlon, Joseph T, PharmD, MS, Semla, Todd P. MS, PharmD and Schmader, Kenneth E. MD. Alternative Medications for Medications in the Use of High-Risk Medications in the Elderly and Potentially Harmful Drug-Disease Interactions in the Elderly Quality Measures. Journal of American Geriatrics Society.2015.
- 13. The American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. American Geriatrics Society. 2019.
- 14. Dayvigo [package insert]. Woodcliff Lake, NJ: Eisai; December 2019.